- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of October 5
Here are the top 5 biosimilar articles for the week of October 5, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of October 5, 2020.
Number 5: The European Medicines Agency has initiated review of a proposed ranibizumab biosimilar (SB11) from Samsung Bioepis.
Number 4:Of the 54 biosimilars approved by the European Medicines Agency (EMA) as of August 2019, fewer than half are available in Slovakia, but if the remaining 30 biosimilars were available, the nation’s health fund could save between €35 million and €50 million per year, according to a new study.
Number 3: A group of researchers from the biosimilar industry and academia have recommended in a review that the FDA widen the scope of acceptable studies for determining interchangeable status for biosimilars.
Number 2: According to a report from the IQVIA Institute for Human Data Science, biosimilars could generate sales of $80 billion over the next 5 years and potential biosimilar-generated health care savings could reach more than $100 billion during that same period.
Number 1: Accord brought 2 biosimilars referencing blockbuster oncology products to the United Kingdom and amended its agreement with Shanghai Henlius Biotech.
To read all of these articles and more, visit centerforbiosimilars.com.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
